Loading...
XWARKRK
Market cap4.52bUSD
Dec 20, Last price  
596.00PLN
1D
2.41%
1Q
2.41%
Jan 2017
140.32%
Name

Krka dd Novo Mesto

Chart & Performance

D1W1MN
XWAR:KRK chart
P/E
13.81
P/S
2.40
EPS
10.14
Div Yield, %
1.11%
Shrs. gr., 5y
-0.66%
Rev. gr., 5y
6.28%
Revenues
1.81b
+5.18%
1,010,021,0001,075,627,0001,143,301,0001,200,827,0001,191,614,0001,164,607,0001,174,424,0001,266,392,0001,331,858,0001,493,409,0001,534,941,0001,565,802,0001,717,453,0001,806,391,000
Net income
314m
-13.58%
171,025,000162,801,000159,915,000172,836,000166,221,000158,245,000108,452,000152,600,000174,585,000245,545,000290,995,000309,214,000363,296,000313,946,000
CFO
227m
-51.41%
181,516,000247,058,000278,329,000302,751,000170,870,000277,941,000213,492,000227,827,000289,952,000349,523,000360,759,000386,097,000467,651,000227,254,000
Dividend
Jul 23, 202432.034 PLN/sh
Earnings
May 14, 2025

Profile

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular diseases; the gastrointestinal tract; central nervous system; pain relief; anti-infectives; blood and blood-forming organs; urological; diabetes; and oncology. The company also provides non-prescription products, such as products for oral cavity and pharynx; cough and cold products; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others. In addition, it offers animal health products comprising antiinfectives, antiparasitics, and other products for farm and companion animals. Further, the company provides health resort and tourist services. Krka, d. d. was founded in 1954 and is headquartered in Novo Mesto, Slovenia.
URL
https://www.krka.si/
IPO date
Feb 10, 1997
Employees
11,653
Domiciled in
SI
Incorporated in
SI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,806,391
5.18%
1,717,453
9.69%
1,565,802
2.01%
Cost of revenue
1,412,917
1,345,439
1,222,390
Unusual Expense (Income)
NOPBT
393,474
372,014
343,412
NOPBT Margin
21.78%
21.66%
21.93%
Operating Taxes
53,394
69,411
54,267
Tax Rate
13.57%
18.66%
15.80%
NOPAT
340,080
302,603
289,145
Net income
313,946
-13.58%
363,296
17.49%
309,214
6.26%
Dividends
(204,379)
(175,044)
(155,907)
Dividend yield
Proceeds from repurchase of equity
(13,923)
(6,099)
(11,747)
BB yield
Debt
Debt current
3,452
3,752
3,433
Long-term debt
20,546
19,930
20,881
Deferred revenue
6,048
6,875
Other long-term liabilities
140,671
107,235
136,153
Net debt
(504,456)
(606,022)
(244,407)
Cash flow
Cash from operating activities
227,254
467,651
386,097
CAPEX
(130,024)
(94,732)
(72,127)
Cash from investing activities
(343,235)
76,414
(372,637)
Cash from financing activities
(229,822)
(187,022)
(169,850)
FCF
85,951
470,833
210,505
Balance
Cash
480,780
569,631
313,795
Long term investments
47,674
60,073
(45,074)
Excess cash
438,134
543,831
190,431
Stockholders' equity
2,259,348
2,112,188
1,888,549
Invested Capital
1,896,302
1,691,608
1,876,816
ROIC
18.96%
16.96%
16.38%
ROCE
16.86%
16.56%
16.52%
EV
Common stock shares outstanding
30,954
31,071
31,185
Price
Market cap
EV
EBITDA
498,068
479,698
452,249
EV/EBITDA
Interest
1,261
495
Interest/NOPBT
0.34%
0.14%